TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04706520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Beverage Consumption
Description: All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Beverage Consumption
Description: All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study Beverage Consumption
Description: All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
Study: NCT06493370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid/vitamin C
Description: A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
Study: NCT04572347

Intervention type: OTHER
Intervention: Observational
Description: It is an observational study, and no intervention will be provided.
Study: NCT05869019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Premature baby care training will be provided.
Study: NCT04959721

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection with triamcinolone acetonide, bupivacaine, and normal saline
Description: Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast.
Study: NCT04191902

Intervention type: BEHAVIORAL
Intervention: orientation
Description: patients will be oriented
Study: NCT06144931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
Study: NCT05718908

Intervention type: DIETARY_SUPPLEMENT
Intervention: Food supplement
Description: FibrofixPlus® is an authorized food supplement.
Study: NCT00893490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve (AGV)
Description: AGV implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve (AGV)
Description: AGV implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Valve (AGV)
Description: AGV implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: 3 minute MMC application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amniotic membrane coverage
Description: single layer coverage of amniotic membrane
Study: NCT06515548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 mouth wash
Description: topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 mouth wash
Description: topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
Study: NCT04885816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon (DEB)
Description: Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stents (DES)
Description: Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines.
Study: NCT05420818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversalis Fascia Inversion
Description: This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
Study: NCT05323305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided regional block
Description: Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided regional block
Description: Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
Study: NCT05284045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detailed information
Description: Subjects in this arm will receive usual information + detailed information on side effects
Study: NCT05720832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WINGS-IP1 Smartphone Application
Description: The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content.
Study: NCT05040217

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-BDNF Gene Therapy
Description: AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-BDNF Gene Therapy
Description: Gene therapy is a biological therapy delivering the BDNF gene to the brain
Study: NCT05414240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical management
Description: All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
Study: NCT06301165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC induction chemotherapy
Description: TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP induction chemotherapy
Description: GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
Study: NCT05535842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLOW
Description: GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
Study: NCT06074926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Associative Conditioning
Description: There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated Exposure
Description: There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
Study: NCT04922593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010; paliperidone palmitate
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INVEGA SUSTENNA
Description: INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
Study: NCT05884034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
Study: NCT05873387

Intervention type: DEVICE
Intervention: Use of Eko DUO stethoscope (paired ECG/PCG)
Description: Auscultation of heart sounds using electronic stethoscope

Intervention type: DEVICE
Intervention: Use of Eko DUO stethoscope (paired ECG/PCG)
Description: Auscultation of heart sounds using electronic stethoscope
Study: NCT05795933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
Study: NCT05235529

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Surgery replacement od the aortic valve

Intervention type: DEVICE
Intervention: TAVI
Description: Transcatheter aortic valve implantation
Study: NCT05474794

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DFI-EUS
Description: All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CE-EUS
Description: Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour.
Study: NCT05225272

Intervention type: OTHER
Intervention: Enhanced Recovery Program for on-pump cardiac surgery
Description: Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
Study: NCT06566807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib, obinutuzumab
Description: orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
Study: NCT06073873

Intervention type: DRUG
Intervention: Ozanimod
Description: According to local product label
Study: NCT03925116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COntraceptive pathway
Description: alternative way of aiding patients in deciding contraception method
Study: NCT05631652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillSense System
Description: The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
Study: NCT04865094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06567184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Hearts Urban
Description: A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
Study: NCT05910450

Intervention type: DRUG
Group type: OTHER
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
Study: NCT06567951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Description: This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
Study: NCT06557473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: 1.5mg/kg IV for induction of GA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl IV 2 µg/kg for GA induction
Study: NCT06566859

Intervention type: OTHER
Intervention: NRS 0. hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 0. hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 6. Hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 6. Hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 12. Hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 12. Hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 24. Hour
Description: Numerical rating scala

Intervention type: OTHER
Intervention: NRS 24. Hour
Description: Numerical rating scala
Study: NCT06567626

Intervention type: OTHER
Intervention: Decision Support Tool (DECIDE-CAD)
Description: DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
Study: NCT05217368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandala painting
Description: In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
Study: NCT04815408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: PD-1 antibody，Tislelizumab (BGB-A317)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
Description: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
Description: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
Study: NCT05880537

Intervention type: OTHER
Intervention: Nexeon Arterial Venous Allograft
Description: Nexeon AVX allograft for hemodialysis access in end stage renal disease
Study: NCT05553028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computerised tomography
Description: Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computerised tomography
Description: Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
Study: NCT05217368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antenatal education
Description: Routine antenatal education will be given.